Effect of Epicatechin against Radiation-Induced Oral Mucositis: In Vitro and In Vivo Study

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Shin, Yoo Seob ^a   Shin, Hyang Ae ^b   Kang, Sung Un ^a   Kim, Jang Hee ^a   Oh, Young Taek ^a   Park, Keun Hyung ^a   Kim, Chul Ho ^a  

^a Ajou University School of Medicine   (South Korea)

^b National Health Insurance Corporation   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; EPICATECHIN; MITOGEN ACTIVATED PROTEIN KINASE P38; REACTIVE OXYGEN METABOLITE; STRESS ACTIVATED PROTEIN KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KERATINOCYTE; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUTH MUCOSA; NICK END LABELING; NONHUMAN; ORAL MUCOSITIS; RADIATION INJURY; RADIATION PROTECTION; RAT; SIGNAL TRANSDUCTION; SURVIVAL RATE; WEIGHT REDUCTION;

ANALYSIS OF VARIANCE; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CATECHIN; FEMALE; FLUORESCEIN-5-ISOTHIOCYANATE; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; KERATINOCYTES; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICROSCOPY, FLUORESCENCE; PROPIDIUM; RADIOTHERAPY; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; STOMATITIS;

EID: 84880432682     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0069151     Document Type: Article

References (40)

1. Sankaranarayanan R, Masuyer E, Swaminathan R, Ferlay J, Whelan S, (1998) Head and neck cancer: a global perspective on epidemiology and prognosis. Anticancer Res 18: 4779-4786.
2. Pignon JP, Bourhis J, Domenge C, Designe L, (2000) Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 355: 949-955.
3. Epstein JB, Gorsky M, Guglietta A, Le N, Sonis ST, (2000) The correlation between epidermal growth factor levels in saliva and the severity of oral mucositis during oropharyngeal radiation therapy. Cancer 89: 2258-2265.
4. Epstein JB, Robertson M, Emerton S, Phillips N, Stevenson-Moore P, (2001) Quality of life and oral function in patients treated with radiation therapy for head and neck cancer. Head Neck 23: 389-398.
5. Plevova P, (1999) Prevention and treatment of chemotherapy- and radiotherapy-induced oral mucositis: a review. Oral Oncol 35: 453-470.
6. Antunes HS, de Azevedo AM, da Silva Bouzas LF, Adao CA, Pinheiro CT, et al. (2007) Low-power laser in the prevention of induced oral mucositis in bone marrow transplantation patients: a randomized trial. Blood 109: 2250-2255.
7. Leborgne JH, Leborgne F, Zubizarreta E, Ortega B, Mezzera J, (1998) Corticosteroids and radiation mucositis in head and neck cancer. A double-blind placebo-controlled randomized trial. Radiother Oncol 47: 145-148.
8. Epstein JB, Silverman S Jr, Paggiarino DA, Crockett S, Schubert MM, et al. (2001) Benzydamine HCl for prophylaxis of radiation-induced oral mucositis: results from a multicenter, randomized, double-blind, placebo-controlled clinical trial. Cancer 92: 875-885.
9. Trotti A, Garden A, Warde P, Symonds P, Langer C, et al. (2004) A multinational, randomized phase III trial of iseganan HCl oral solution for reducing the severity of oral mucositis in patients receiving radiotherapy for head-and-neck malignancy. Int J Radiat Oncol Biol Phys 58: 674-681.
10. Brizel DM, Wasserman TH, Henke M, Strnad V, Rudat V, et al. (2000) Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 18: 3339-3345.
11. Rosenthal DI, Trotti A, (2009) Strategies for managing radiation-induced mucositis in head and neck cancer. Semin Radiat Oncol 19: 29-34.
12. Rovirosa A, Ferre J, Biete A, (1998) Granulocyte macrophage-colony-stimulating factor mouthwashes heal oral ulcers during head and neck radiotherapy. Int J Radiat Oncol Biol Phys 41: 747-754.
13. Hille A, Rave-Frank M, Pradier O, Damm C, Dorr W, et al. (2003) Effect of keratinocyte growth factor on the proliferation, clonogenic capacity and colony size of human epithelial tumour cells in vitro. Int J Radiat Biol 79: 119-128.
14. Spielberger R, Stiff P, Bensinger W, Gentile T, Weisdorf D, et al. (2004) Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 351: 2590-2598.
15. Lee SW, Jung KI, Kim YW, Jung HD, Kim HS, et al. (2007) Effect of epidermal growth factor against radiotherapy-induced oral mucositis in rats. Int J Radiat Oncol Biol Phys 67: 1172-1178.
16. Wilkes JD, (1998) Prevention and treatment of oral mucositis following cancer chemotherapy. Semin Oncol 25: 538-551.
17. Sonis ST, Lindquist L, Van Vugt A, Stewart AA, Stam K, et al. (1994) Prevention of chemotherapy-induced ulcerative mucositis by transforming growth factor beta 3. Cancer Res 54: 1135-1138.
18. Sheng-Tanner X, Bump EA, Hedley DW, (1998) An oxidative stress-mediated death pathway in irradiated human leukemia cells mapped using multilaser flow cytometry. Radiat Res 150: 636-647.
19. Lalla RV, Peterson DE, (2006) Treatment of mucositis, including new medications. Cancer J 12: 348-354.
20. Suntharalingam M, Jaboin J, Taylor R, Wolf J, Banglore M, et al. (2004) The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT). Semin Oncol 31: 2-7.
21. Schroeder P, Klotz LO, Sies H, (2003) Amphiphilic properties of (-)-epicatechin and their significance for protection of cells against peroxynitrite. Biochem Biophys Res Commun 307: 69-73.
22. Shin YS, Song SJ, Kang SU, Hwang HS, Choi JW, et al. (2012) A novel synthetic compound, 3-amino-3-(4-fluoro-phenyl)-1H-quinoline-2,4-dione, inhibits cisplatin-induced hearing loss by the suppression of reactive oxygen species: In vitro and in vivo study. Neuroscience 232C: 1-12.
23. Sonis ST, (2002) The biologic role for nuclear factor-kappaB in disease and its potential involvement in mucosal injury associated with anti-neoplastic therapy. Crit Rev Oral Biol Med 13: 380-389.
24. Siomek A, Tujakowski J, Gackowski D, Rozalski R, Foksinski M, et al. (2006) Severe oxidatively damaged DNA after cisplatin treatment of cancer patients. Int J Cancer 119: 2228-2230.
25. Cho SA, Park JH, Seok SH, Juhn JH, Kim SJ, et al. (2006) Effect of granulocyte macrophage-colony stimulating factor (GM-CSF) on 5-FU-induced ulcerative mucositis in hamster buccal pouches. Exp Toxicol Pathol 57: 321-328.
26. Kim CH, Kang SU, Pyun J, Lee MH, Hwang HS, et al. (2008) Epicatechin protects auditory cells against cisplatin-induced death. Apoptosis 13: 1184-1194.
27. Lee JS, Kang SU, Hwang HS, Pyun JH, Choung YH, et al. (2010) Epicatechin protects the auditory organ by attenuating cisplatin-induced ototoxicity through inhibition of ERK. Toxicol Lett 199: 308-316.
28. Pyun JH, Kang SU, Hwang HS, Oh YT, Kang SH, et al. (2011) Epicatechin inhibits radiation-induced auditory cell death by suppression of reactive oxygen species generation. Neuroscience 199: 410-420.
29. Guo Q, Zhao B, Li M, Shen S, Xin W, (1996) Studies on protective mechanisms of four components of green tea polyphenols against lipid peroxidation in synaptosomes. Biochim Biophys Acta 1304: 210-222.
30. Higdon JV, Frei B, (2003) Tea catechins and polyphenols: health effects, metabolism, and antioxidant functions. Crit Rev Food Sci Nutr 43: 89-143.
31. de Mejia EG, Ramirez-Mares MV, Puangpraphant S, (2009) Bioactive components of tea: cancer, inflammation and behavior. Brain Behav Immun 23: 721-731.
32. Chung JY, Huang C, Meng X, Dong Z, Yang CS, (1999) Inhibition of activator protein 1 activity and cell growth by purified green tea and black tea polyphenols in H-ras-transformed cells: structure-activity relationship and mechanisms involved. Cancer Res 59: 4610-4617.
33. Chung JY, Park JO, Phyu H, Dong Z, Yang CS, (2001) Mechanisms of inhibition of the Ras-MAP kinase signaling pathway in 30.7b Ras 12 cells by tea polyphenols (-)-epigallocatechin-3-gallate and theaflavin-3,3′-digallate. FASEB J 15: 2022-2024.
34. Schroeter H, Bahia P, Spencer JP, Sheppard O, Rattray M, et al. (2007) (-)Epicatechin stimulates ERK-dependent cyclic AMP response element activity and up-regulates GluR2 in cortical neurons. J Neurochem 101: 1596-1606.
35. Cai J, Yang J, Jones DP, (1998) Mitochondrial control of apoptosis: the role of cytochrome c. Biochim Biophys Acta 1366: 139-149.
36. Stanely Mainzen Prince P, (2013) (-) Epicatechin attenuates mitochondrial damage by enhancing mitochondrial multi-marker enzymes, adenosine triphosphate and lowering calcium in isoproterenol induced myocardial infarcted rats. Food Chem Toxicol 53: 409-416.
37. Murphy CK, Fey EG, Watkins BA, Wong V, Rothstein D, et al. (2008) Efficacy of superoxide dismutase mimetic M40403 in attenuating radiation-induced oral mucositis in hamsters. Clin Cancer Res 14: 4292-4297.
38. Artali R, Beretta G, Morazzoni P, Bombardelli E, Meneghetti F, (2009) Green tea catechins in chemoprevention of cancer: a molecular docking investigation into their interaction with glutathione S-transferase (GST P1-1). J Enzyme Inhib Med Chem 24: 287-295.
39. Mann CD, Neal CP, Garcea G, Manson MM, Dennison AR, et al. (2009) Phytochemicals as potential chemopreventive and chemotherapeutic agents in hepatocarcinogenesis. Eur J Cancer Prev 18: 13-25.
40. Kuo YC, Yu CL, Liu CY, Wang SF, Pan PC, et al. (2009) A population-based, case-control study of green tea consumption and leukemia risk in southwestern Taiwan. Cancer Causes Control 20: 57-65.